Regeneron Pharmaceuticals' Invested Capital rose 203.87% to $32.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $32.0 billion, marking a year-over-year increase of 203.87%. This contributed to the annual value of $32.0 billion for FY2025, which is 203.87% up from last year.
Per Regeneron Pharmaceuticals' latest filing, its Invested Capital stood at $32.0 billion for Q4 2025, which was up 203.87% from $31.0 billion recorded in Q3 2025.
Regeneron Pharmaceuticals' Invested Capital's 5-year high stood at $32.0 billion during Q4 2025, with a 5-year trough of $14.0 billion in Q1 2021.
Over the past 5 years, Regeneron Pharmaceuticals' median Invested Capital value was $24.8 billion (recorded in 2022), while the average stood at $25.1 billion.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Invested Capital surged by 8999.16% in 2021, and later skyrocketed by 203.87% in 2025.
Regeneron Pharmaceuticals' Invested Capital (Quarter) stood at $20.7 billion in 2021, then increased by 18.78% to $24.6 billion in 2022, then grew by 13.43% to $28.0 billion in 2023, then grew by 12.1% to $31.3 billion in 2024, then increased by 2.04% to $32.0 billion in 2025.
Its Invested Capital was $32.0 billion in Q4 2025, compared to $31.0 billion in Q3 2025 and $29.9 billion in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value